As increased EN-RAGE levels have been demonstrated in T1D patients [18], and increased levels of HbA1c have been linked to higher levels of EN-RAGE in both T2D patients and non-diabetics [10], the indications for treatment with LLD should perhaps be supplemented with unsatisfactory glycemic control in patients with T1D, provided it can be further confirmed that LLD may decrease EN-RAGE levels. The gene discussed is AGER; the disease is type 1 diabetes mellitus.